Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

48.58 +0.99 (+2.08%)

Streaming Delayed Price Updated: 2:41 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma

June 20, 2025

From Genentech

Via Business Wire

MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars ↗

June 18, 2025

The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.

Via Stocktwits

Roche Stock Slides After Failed Blood Cancer Trial With AbbVie, But Parkinson’s Therapy Progress Boosts Retail Mood ↗

June 16, 2025

The Swiss pharma giant advanced its anti-alpha-synuclein antibody prasinezumab to the next stage based on promising Phase IIb data.

Via Stocktwits

Genentech Provides Update on Phase III Verona Study

June 16, 2025

From Genentech

Via Business Wire

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy ↗

June 16, 2025

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause.

Via Benzinga

Topics Death

Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson’s Disease

June 16, 2025

From Genentech

Via Business Wire

Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy ↗

June 09, 2025

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly.

Via Benzinga

Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study ↗

June 03, 2025

Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung cancer patients.

Via Benzinga

Genentech’s Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer

June 02, 2025

From Genentech

Via Business Wire

How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma ↗

June 02, 2025

Three new cancer drugs could help make a dent in the company's ambitious plans for 2030.

Via Investor's Business Daily

New Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer

May 31, 2025

From Genentech

Via Business Wire

Roche's Multiple Sclerosis Drug Shows Low Disease Activity Over Two Years ↗

May 30, 2025

Roche shares new data showing its MS drug fenebrutinib maintained low relapse rates and no disability progression in patients over 96 weeks.

Via Benzinga

Genentech’s Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis

May 30, 2025

From Genentech

Via Business Wire

Roche Gets Positive Opinion For Approval Of Cancer Therapy In EU: Retail Yet To React ↗

May 23, 2025

The company said that the European Commission is expected to make a decision soon regarding the approval for Itovebi.

Via Stocktwits

Topics Government

New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients

May 23, 2025

From Genentech

Via Business Wire

FDA Approves Genentech’s Susvimo for Diabetic Retinopathy

May 22, 2025

From Genentech

Via Business Wire

The Smartest Vanguard ETF to Buy With $500 Right Now ↗

May 21, 2025

Via The Motley Fool

Topics ETFs

Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

May 20, 2025

From Genentech

Via Business Wire

Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price ↗

May 16, 2025

Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.

Via Investor's Business Daily

Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda ↗

May 15, 2025

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.

Via Benzinga

Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030 ↗

May 14, 2025

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.

Via Benzinga

FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases ↗

May 14, 2025

FDA grants accelerated approval to AbbVie's Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes $335 million upfront.

Via Benzinga

Why Weight-Loss Developer Stocks Tumbled on Tuesday ↗

May 13, 2025

Via The Motley Fool

Topics Government

Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17% ↗

May 13, 2025

Roche's APHINITY study shows promising results for HER2-positive breast cancer treatment with Perjeta regime

Via Benzinga

Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer

May 13, 2025

From Genentech

Via Business Wire

Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say ↗

May 12, 2025

JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting...

Via Stocktwits

Topics ETFs Government Stocks

S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform ↗

May 12, 2025

It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices.

Via Investor's Business Daily

Topics Government Stocks

Roche and Genentech Announce New North Carolina Manufacturing Facility

May 12, 2025

From Genentech

Via Business Wire

Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots ↗

May 12, 2025

Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space.

Via Benzinga

Topics Artificial Intelligence

Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket ↗

May 12, 2025

What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription...

Via Benzinga

Topics Government

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.